Spark Biomedical Awarded $1.15M Department of Defense Phase II STTR Grant in Partnership with Battelle Memorial Institute
29 août 2023 14h52 HE
|
Spark Biomedical
DALLAS, Texas, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aug. 29, 2023 — Spark Biomedical, Inc., a Dallas-based pioneer in wearable neurostimulation technology, was awarded a $1.15M Phase II grant to...
Spark Biomedical Launches Telehealth Services for Sparrow Ascent, Improving Patient Access to Opioid Withdrawal Treatment
08 août 2023 12h05 HE
|
Spark Biomedical
DALLAS, TX, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical Launches Telehealth Services for Sparrow Ascent, Improving Patient Access to Opioid Withdrawal Treatment August 8, 2023, Dallas, TX...
Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults
11 juil. 2023 14h54 HE
|
Spark Biomedical
DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults
11 juil. 2023 14h38 HE
|
Spark Biomedical
DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults
11 juil. 2023 14h31 HE
|
Spark Biomedical
DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
Spark Biomedical, Inc., granted $2.49M by the National Institute of Health HEAL Initiative to use neuromodulation as adjunctive therapy for neonatal opioid withdrawal syndrome
03 mars 2022 11h22 HE
|
Spark Biomedical
Dallas, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Building on Phase I clinical trial success (Jenkins, Khodaparast, et al., 2021), Spark Biomedical, Inc., and The Medical University of South...
Spark Biomedical, Inc enlists the expertise of former Deputy Secretary of the U.S. Department of Health and Human Services, Eric D. Hargan, to help make novel opioid withdrawal treatment more accessible and affordable for patients
04 nov. 2021 10h25 HE
|
Spark Biomedical
Dallas, TX, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc, a leader in wearable neurostimulation for opioid withdrawal relief, today announced the Company will join forces with Eric D....